Conference Abstracts - 2026 National Summit on Hematologic Cancers
Vol. 6, Issue Supplement 2, 2026 · S1-2
Real World Experience of Anakinra for the Treatment of Corticosteroids-Refractory Neurotoxicity in Large B-cell Lymphoma
Sara El Mustapha, MD,Rahul Shah, MD,Xiaowen Sun, Research Biostatistician, PhD,Lei Feng, Principal Biostatistician, MSc,Anath C Lionel, MD,Zachary Erin Hunzeker, MD,Sairah Ahmed, MD,Jeremy Leon Ramdial, MD,Michelly R De Castro, APRN,Karla V Ow, APRN,Minifrida S Santiago, APRN,Jaimole T Varghese, APRN,Sherry Adkins, APP, Supv, MSN,Misha C Hawkins, MSN, RN, OCN,Sandra B Horowits, PharmD,Amy A Ayers, Program Director,Partow Kebriaei, MD,Elizabeth Shpall, MD,Sattva S Neelapu, MD,Paolo Strati, MD
Submission received: 2026-08-15 / Accepted: 2026-08-25 / Published: 2026-09-25
Abstract
Background
The NCCN guidelines suggest the use of anakinra, an IL-1 receptor antagonist, for the treatment of CART-associated corticosteroids-refractory ICANS, based on a retrospective study including 37 patients with B-cell lymphoma (category 2A). Additional real-world experience, supporting its use and guiding treatment selection and monitoring, is needed.
Methods
This retrospective single center study included patients with large B-cell lymphoma (LBCL), who were treated with anakinra for corticosteroids-refractory ICANS after CART, between 09/2018 and 11/2024, with follow-up through 06/2026. Responders to anakinra were defined as patients who achieved full resolution of ICANS. Serum inflammatory and tumor burden biomarkers were collected daily through at least day +10 (longer in case of ICANS), then twice weekly until day +30. Association between categorical variables were evaluated using the chi-square or Fisher's exact test, and differences in continuous variables between patients' groups were compared using the Wilcoxon rank sum test.
Results
Forty-six patients with LBCL were included in this study, 40 (87%) were treated with axicabtagene ciloleucel. Anakinra was administered at a median daily dose of 100 mg (range, 100-800 mg) for a median duration of 7 days (range, 1-14), either SC or IV. At time of anakinra initiation, median received cumulative dexamethasone equivalent dose was 65 mg (range, 30- 1344 mg). Thirty-three (72%) patients responded to anakinra, and associated factors included: lower prior cumulative dexamethasone equivalent dose (median 40 vs 180 mg, p=0.0119), higher hemoglobin (median 10.2 vs 8.5 g/dL, p=0.0073), lower CRP (median 11.3 vs 73.0 mg/dL, p=0.0060), and lower LDH (median 219 vs 367 U/L, p=0.007). During the first 30 days after CART, responders had a significantly lower AUC for CRP (median 602 vs 1166 mg x day/L, p=0.0180), but not for ferritin nor for LDH.
Conclusion
In a real-world setting, anakinra demonstrated clinical activity in >70% of patients with corticosteroids-refractory ICANS. Greater benefit was observed in patients with lower inflammatory markers and shorter prior corticosteroids exposure, with CRP emerging as the most predictive biomarker of response.
